DiappyMed Raises €5M to Scale Digital Diabetes Therapy Across France

The digital therapeutics market for diabetes management is experiencing rapid growth across Europe, as healthcare systems increasingly recognise the potential of software-based interventions to improve patient outcomes and reduce costs. France, with an estimated 4.2 million people living with diabetes, stands at the forefront of this transformation — and one Montpellier-based startup is positioning itself to lead the charge.

DiappyMed, the French medtech company behind the clinically validated insulin dose calculation app EkiYou, has raised €5 million in a seed funding round. The investment was led by Ventech and AFI Ventures, with additional participation from Sofilaro and IRDI Capital Investissement. Alongside the raise, DiappyMed has announced a strategic partnership with pharmaceutical giant Sanofi to accelerate the deployment of its digital therapy across France.

Ventech and Sanofi Back Personalised Diabetes Care

The seed round marks a significant milestone for DiappyMed, which was founded in January 2021 following research conducted at Montpellier University Hospital by co-founder Omar Diouri. The company’s flagship product, EkiYou, is the first digital therapy application in France to have demonstrated clinically proven improvements in postprandial glycaemia within target range — a critical metric for effective diabetes management.

EkiYou works by calculating the appropriate insulin dose for patients based on their meals, physical activity levels, and blood glucose readings. The application effectively replaces the complex mental arithmetic that many insulin-dependent patients must perform daily, reducing dosing errors and improving glycaemic control. DiappyMed also launched EkiYou Carbs in November 2022, a complementary carbohydrate counting tool co-developed with Montpellier University Hospital.

The partnership with Sanofi is particularly noteworthy. The collaboration aims to massively deploy EkiYou as the first French digital therapy dedicated to personalised insulin
dose calculation for both healthcare professionals and patients living with diabetes. Sanofi’s involvement brings not only commercial reach but also deep expertise in insulin therapy, positioning DiappyMed at the intersection of pharmaceutical and digital health innovation.

European Digital Therapeutics Market Gains Momentum

DiappyMed’s raise arrives at an opportune moment for the digital therapeutics sector. The global market for digital therapeutics in diabetes management was valued at approximately $1.6 billion in 2023 and is projected to reach $5.3 billion by 2033, according to industry estimates. In Europe, regulatory frameworks are evolving to accommodate digital health solutions, with France’s health insurance system moving towards reimbursement of validated digital therapies.

Indeed, a central objective for DiappyMed is to achieve reimbursement from the French national health insurance (Assurance Maladie) in 2026. Securing reimbursement would represent a transformative moment for the company, as it would effectively integrate EkiYou into the standard care pathway for insulin-dependent diabetes patients across France — dramatically expanding its addressable market and providing a template for expansion into other European healthcare systems.

The €5 million investment will support DiappyMed’s pursuit of this reimbursement milestone, whilst also funding further clinical development, platform enhancements, and the scaling of its commercial partnership with Sanofi. As European healthcare systems grapple with rising diabetes prevalence and mounting treatment costs, digitally enabled solutions like EkiYou represent a compelling proposition for payers, providers, and patients alike.

Summary